Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10

In previous studies, children immunized with a formalin-inactivated respiratory syncytial virus vaccine (FI-RSV) developed severe pulmonary disease with greater frequency than did controls during subsequent natural RSV infection. In earlier efforts to develop an animal model for this phenomenon, extensive pulmonary histopathology developed in FI-RSV-immunized cotton rats and mice subsequently challenged with RSV. In mice, depletion of CD4+ T cells at the time of RSV challenge completely abrogated this histopathology. Furthermore, the predominant cytokine mRNA present in lungs of FI-RSV-immunized mice during subsequent infection with RSV was that characteristically secreted by Th2 T cells, namely interleukin-4 (IL-4). In the present studies, we sought to determine the relative contributions of gamma interferon (IFN-gamma), IL-2, IL-4, and IL-10 to the lymphocytic infiltration into the lungs observed following RSV challenge of mice previously immunized with FI-RSV. Mice previously immunized with FI-RSV or infected with RSV were depleted of IFN-gamma, IL-2, IL-4, or IL-10 immediately before RSV challenge, and the magnitude of inflammatory cell infiltration around bronchioles and pulmonary blood vessels was quantified. The phenomenon of pulmonary-histopathology potentiation by FI-RSV was reproduced in the present study, thereby allowing us to investigate the effect of cytokine depletion on the process. Simultaneous depletion of both IL-4 and IL-10 completely abrogated pulmonary histopathology in FI-RSV-immunized mice. Depletion of IL-4 alone significantly reduced bronchiolar, though not perivascular, histopathology. Depletion of IL-10 alone had no effect. Depletion of IFN-gamma, IL-2, or both together had no effect on the observed histopathology. These data indicate that FI-RSV immunization primes for a Th2-, IL-4-, and IL-10-dependent inflammatory response to subsequent RSV infection. It is possible that this process played a role in enhanced disease observed in infants and children immunized with FI-RSV.

[1]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[2]  B. Graham,et al.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. , 1993, Journal of immunology.

[3]  R. Locksley.  Interleukin 12 in host defense against microbial pathogens. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[5]  P. Openshaw,et al.  Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. , 1993, Vaccine.

[6]  B. Murphy,et al.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells , 1992, Journal of virology.

[7]  B. Aggarwal,et al.  In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria , 1992, Infection and immunity.

[8]  R. Chanock,et al.  Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. , 1992, Pediatrics.

[9]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[10]  K. Weinberg,et al.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[11]  R. Chanock,et al.  Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. , 1992, Vaccine.

[12]  S. Romagnani.  Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. , 1992, International archives of allergy and immunology.

[13]  J. Chapsal,et al.  Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. , 1992, Vaccine.

[14]  R. Brideau,et al.  A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. , 1991, Vaccine.

[15]  P. Puccetti,et al.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance , 1991, Infection and immunity.

[16]  B. Graham,et al.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. , 1991, The Journal of clinical investigation.

[17]  B. Graham,et al.  Reinfection of mice with respiratory syncytial virus , 1991, Journal of medical virology.

[18]  S. Durham,et al.  Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects , 1991, The Journal of experimental medicine.

[19]  A. Sher,et al.  Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni , 1991, The Journal of experimental medicine.

[20]  P. Collins,et al.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins , 1990, Journal of virology.

[21]  R. Chanock,et al.  Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. , 1989, Vaccine.

[22]  R. Coffman,et al.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , 1988, The Journal of experimental medicine.

[23]  T. Braciale,et al.  Antigen form influences induction and frequency of influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes. , 1988, Journal of immunology.

[24]  E. Walsh,et al.  Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine , 1986, Journal of clinical microbiology.

[25]  E. Walsh,et al.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus , 1986, Journal of virology.

[26]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[27]  R. Chanock,et al.  The pathogenesis of respiratory syncytial virus infection in cotton rats. , 1978, The American journal of pathology.

[28]  R. Chanock,et al.  Cell-mediated Immunity to Respiratory Syncytial Virus Induced by Inactivated Vaccine or by Infection , 1976, Pediatric Research.

[29]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[30]  E. H. Lennette,et al.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. , 1969, American journal of epidemiology.